Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Preparation process validation

Raffin, R. P., Jornada, D. S., Re, M. L, Pohimann, A. R. Guterres, S. S. (2006). Sodium pantoprazole-loaded enteric microparticles prepared by spray drying Effect of the scale of production and process validation. International Journal of Pharmaceutics, Vol. 324,1, (October 2006), pp. (10-18), ISSN 0378-5173... [Pg.82]

This procedure provides the information required to support the sterility assurance of the drug product (product name), USP, manufactured by ABC Pharmaceutical Industries. It references the FDA Guidance titled Guidance for Industry for the Submission of Documentation for Sterilization Process Validation in Applications for Human and Veterinary Dmg Products prepared by the Sterility Technical Committee of the Chemistry Manufacturing Controls Coordinating Committee of the Center for Dmg Evaluation and Research (CDER) and the Center for Veterinary Medicine (CVM) in November of 1994. [Pg.478]

The steps and sequence of events required to carry out a process validation assignment are outlined in Table 8. The objective of prospective validation is to prove or demonstrate that the process will work in accordance with a validation master plan or protocol prepared for pilot-product (100 x size) trials. [Pg.34]

For example, most companies would rather reference their supporting documents than have FDA ask whether or not a particular document exists. Further, this practice will assure that the company has actually taken sufficient time and prepared the document referenced. There are those companies that prefer to voluntarily attach the documents rather than just reference them. This may not be in the best interest of CGMP manufacturers for two clear reasons. First, attaching every development report, every batch record, every analytical method, every support protocol/report and so forth will make a process validation document—a hefty document to begin with—too big to read. Second, volunteering any information is considered very dangerous, as it is very rare for a company to have no dirty laundry. Why hang it out for FDA or any audience to see ... [Pg.310]

Eventually the point will be reached at which the development of a product is complete the formulation is finalized, the equipment has been selected, the analytical methods are validated, the development transfer report has been issued, and the Preapproval Inspection (PAI) is anticipated. Now is the time to consider validation of both the manufacturing and cleaning processes. Although some process validation may have also been completed or a process validation protocol may have been prepared and approved, it is likely that very little has been finished that would enable us to state that the cleaning process is fully validated. [Pg.508]

The pharmaceutical manufacturer must establish effective policies and plans for regulatory compliance and validation to enable individuals to clearly understand the company commitment and requirements. Computer validation planning should ensure an appropriate training program, preparation of validation guidelines and procedures, system GMP compliance risk and criticality assessment, a documented validation strategy and rationale, clearly defined quality-related critical parameters and data for the manufacturing process. [Pg.573]

Preparation of standard procedures Document review Validation glossary Critical parameter assessment GMP criticality and risk analysis Process validation methodology Computerized system validation Preparation of validation plans Preparation of project and quality plans Manufacturing data specification... [Pg.575]

On satisfactory completion of the computer system qualifications, with PQ conducted in conjunction with a successful process validation, a final report must be prepared by the pharmaceutical manufacturer s validation team. This is normally referred to as the validation report. The objective of the report is to give an overview of the results of the execution of the validation program for the computerized operation and to draw a conclusion as to the suitability of the computerized operation for pharmaceutical manufacturing. This may be unconditional use or there may be restrictions. In the latter case the proposed remedial ac-tion(s) must be approved and, as applicable, considered under change control. A schedule to complete any outstanding actions must be documented and progress formally reported. [Pg.627]

As if there needed to be more affirmation regarding the inclusion of data on validation in the application, the EMEA issued the Note for Guidance on Process Validation [40] prepared by the Committee for Proprietary Medicinal Products (CPMP). This came into operation in 2001. [Pg.877]

Emphasis is placed on preparing a validation protocol in which the specific validation experiments and associated acceptance criteria substantiate that the method meets its technical and regulatory objectives. Only after these steps does the process conclude with the performance of the formal validation and generation of the validation report. Finalization of method development (by way of the method validation) is never truly complete, as validation is aliving process that encompasses the ongoing use of the method in various laboratory settings. [Pg.130]

As stressed in refs. 7 and 28b, the standard Mori theory is deeply different in natiu-e from the approach we have developed, which includes in the set of relevant variables both the variable /q (in the example under discussion, the velodty i>) and a few Mori auxiliary variables (in this example only one auxiliary variable, / => w). The auxiliary variable w plays the double role of variable of interest (being coupled to an irrelevant thermal bath and undergoing the influence of a standard fluctuation-dissipation process) and that of simulating the thermal bath of the real variable of interest. This makes it possible to study exdtation and preparation processes within the framework of the Mori theory, the range of validity of which is, however, limited to the case of linear systems. [Pg.23]

Additional publications which have provided acceptance criteria for aseptic processing validation have been prepared by both CEN and PIC. " These have attempted to reconcile the differences between the ISO document and the PDA guidance. The essence of these documents is the following. Ideally the contamination rate should be zero. However, currently the accepted contamination rate should be less than 0.1% with a 95% confidence level. This appears to be an effort to have it both ways, and it is unclear whether the two perspectives can really be reconciled so easily. [Pg.136]

Product Performance Review/Preparation for Process Validation... [Pg.424]

Stage I Product design and development Stage II Preparation of clinical and biobatches Stage III Process scale-up and evaluation Stage IV Formal process validation... [Pg.3932]

A Zymate II Pye system for automated analysis by the Zymark Corporation (USA) with on-line HPLC has been set up and used for content uniformity tests and assays, including process validation, for a variety of drug products in our QC laboratory since January 1992. The robotic system automatically performs the following operations preparation of sample and reference standard solutions, injection into HPLC, HPLC analyses, and generation of reports. [Pg.59]

Process Validation (PV) verifies the performance of the overall product manufacturing process. PV is performed on the entire product manufacturing process, which includes all support, processes, preparation of media, components, buffers, formulation, filtration, filling, and packaging. [Pg.78]

To scale up a chemical process to pilot or commercial-scale operations, a significant laboratory effort is required to define the operating ranges of the critical process parameters. A critical process parameter is any process variable that may potentially affect the product quality or yield. This information is required to prepare a Process Risk Analysis, which is an FDA prerequisite for process validation. Process parameters that are often evaluated as part of the risk analysis include reaction temperature, solvent systems, reaction time, raw material and reagent ratios, rate and orders of addition, agitation, and reaction concentration. If catalysts are employed as part of the process, additional laboratory evaluation may also be required to further define the process limits. Experimental design is often used for the evaluation of critical process parameters to minimize the total laboratory effort (4). [Pg.411]


See other pages where Preparation process validation is mentioned: [Pg.122]    [Pg.122]    [Pg.635]    [Pg.658]    [Pg.252]    [Pg.64]    [Pg.133]    [Pg.332]    [Pg.39]    [Pg.244]    [Pg.96]    [Pg.1265]    [Pg.247]    [Pg.259]    [Pg.320]    [Pg.327]    [Pg.788]    [Pg.33]    [Pg.163]    [Pg.244]    [Pg.101]    [Pg.36]    [Pg.94]    [Pg.129]    [Pg.128]    [Pg.128]    [Pg.129]    [Pg.136]    [Pg.2176]    [Pg.3271]    [Pg.3717]    [Pg.3723]    [Pg.3936]    [Pg.6]    [Pg.549]   
See also in sourсe #XX -- [ Pg.761 , Pg.762 , Pg.763 ]




SEARCH



Preparation processes

© 2024 chempedia.info